One of the effects evaluated of nucleotides in MASLD is the possible reversal of liver damage through improved mitochondrial function; in a study with mice with HFD-induced hepatic steatosis and six human volunteers, it was observed that NAD+-boosting therapy could reverse steatosis by stimulating the exercise-related hormone fibronectin type III domain containing 5, also called irisin [111]. Here, FNDC5 is linked to Hepatic steatosis.